This trial is comparing the side effects of four weeks of radiation therapy versus five days for men with prostate cancer who have had a prostatectomy in the past and an elevated PSA. Real-time MRI guidance is used to deliver treatment and limit the dose to other organs, while increasing the dose to the target. Patients will be required to undergo testing and periodic questionnaires. If the trial shows that five days and four weeks are equivalent, future patients may benefit from added convenience, lower costs, and reduced burden of cancer treatments.
Patients are eligible if they are/have:
- Men aged >=18 with histologically confirmed low or intermediate risk prostate cancer per NCCN guidelines.
- ECOG 0 - 1
- IPSS < 18
- Ability to receive MRI-guided radiotherapy.
- Ability to complete the Expanded Prostate Cancer Index Composite (EPIC) questionnaire.
- Patients with a prior or concurrent disease whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Note: Any patient with a cancer (other than keratinocyte carcinoma or carcinoma in situ or low-grade non-muscle invasive bladder cancer) who has been disease-free for less than 3 years must contact the Principal Investigator.